Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 20/20 | 0.79 |
| ▸ | PPARD | Q03181 | 15/20 | 0.79 |
| ▸ | PPARG | P37231 | 13/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7029283 | 1.00 | PPARA (0.79) | PPARAPPARDPPARG | |
| SCHEMBL14539026 | 0.91 | PPARA (0.91) | PPARAPPARDPPARG | |
| SCHEMBL6487709 | 0.89 | PPARA (1.00) | PPARAPPARDPPARG | |
| SCHEMBL14544683 | 0.89 | PPARA (1.00) | PPARAPPARDPPARG | |
| SCHEMBL14544577 | 0.89 | PPARA (1.00) | PPARAPPARDPPARG | |
| SCHEMBL6487721 | 0.89 | PPARA (1.00) | PPARAPPARDPPARG | |
| SCHEMBL6487718 | 0.89 | PPARA (1.00) | PPARAPPARDPPARG | |
| SCHEMBL5634053 | 0.88 | PPARA (0.85) | PPARAPPARDPPARG | |
| SCHEMBL5634051 | 0.88 | PPARA (0.85) | PPARAPPARDPPARG | |
| SCHEMBL7020023 | 0.87 | PPARA (0.62) | PPARAPPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1276710-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2003-01-22 | — | — | EP | claimed |
| US-6509374-B2 | For therapy of conditinos mediated by Peroxisome Proliferator-Activated Receptors (PPAR) such as diabetes and obesity | NOVO NORDISK A/S (DK) | 2003-01-21 | — | — | US | claimed |
| US-20020022656-A1 | New compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2002-02-21 | — | — | US | claimed |
| WO-2001079150-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-10-25 | — | — | WO | claimed |
| EP-1276710-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2003-01-22 | — | — | EP | disclosed |
| US-6509374-B2 | For therapy of conditinos mediated by Peroxisome Proliferator-Activated Receptors (PPAR) such as diabetes and obesity | NOVO NORDISK A/S (DK) | 2003-01-21 | — | — | US | disclosed |
| US-20020022656-A1 | New compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2002-02-21 | — | — | US | disclosed |
| WO-2001079150-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022656-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | PPARA 3/4885PPARD 2/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.